Phillips-Medisize, a Molex company and specialist in the design and manufacture of drug delivery, diagnostic and medtech devices, has expanded its product portfolio with the introduction of a disposable pen injector.
Paul Chaffin, senior vice president and president of medical and pharmaceutical solutions, Molex, said: “A Pen Injector is an important addition to Phillips-Medisize’s expanding Product and Platform portfolio that empowers Biopharma companies to accelerate the rollout of novel and generic drug treatments at significant economies of scale. This ‘ready-to-go’ solution offers all of the advantages expected from ‘state of the art’ pen designs, while benefiting from our decades of device development and large-volume manufacturing expertise to reduce the challenges of bringing affordable drugs and drug-delivery devices to market.”
A pen injector has been designed to match user expectations and experiences with familiar disposable pen products yet is noticeably smaller than most comparable offerings in the market. As well as its compact form factor, this pen injector features a design with customisable dosing as well as push-button colours to signal different dosing and drug requirements for multiple therapies, including diabetes, fertility, growth hormones, obesity, and osteoporosis.
Sample devices are currently available to support technical evaluation and human factors studies, with clinical devices scheduled for the end of 2023. As a result, this pen injector is strongly positioned to help drug-delivery companies respond to the rapidly rising, billion-unit-plus disposable pen injector market while reducing commercialisation costs and risks.
Phillips-Medisize produces more than close to 400 million medical devices on behalf of its customers each year. Decades of trusted collaborations with pharmaceutical companies have resulted in the production of off-the-shelf device platforms, along with the design, development, and manufacturing of complex or specialised devices and advanced solutions with embedded connectivity.
The Pen Injector Platform joins Phillips-Medisize’s Aria Smart Autoinjector, which was introduced in May 2021 to meet rising demands for innovation, differentiation and sustainability in the digital drug-delivery device market.
